# RDY earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/RDY) · [Earnings tab](https://www.lopjlb.com/stock/RDY?tab=earnings) Updated: 2026-10-23T05:42:51 Quarters analyzed: 8 ## Cross-quarter narrative Across 8 calls for RDY, management tone moved from +0.70 (2025 Q2) to +0.30 (2027 Q1). Latest guidance stance: maintained. Latest desk line: Dr. Reddy's Q1 FY27 revenue fell 5.6% YoY to $853M; EBITDA margin 12.5% (15.4% ex-semaglutide provision). Base business grew double-digits across geographies. Semaglutide API issues led to INR 240 cr provision; supplies expected to resume November. Abatacept BLA goal date December maintained after F ## Latest CallCard · Q1 Dr. Reddy's Q1 FY27 revenue fell 5.6% YoY to $853M; EBITDA margin 12.5% (15.4% ex-semaglutide provision). Base business grew double-digits across geographies. Semaglutide API issues led to INR 240 cr provision; supplies expected to resume November. Abatacept BLA goal date December maintained after F **Guidance:** maintained — Management maintains 20% EBITDA margin target excluding semaglutide, double-digit base business growth, and strong H2 with semaglutide resumption in November. No change to abatacept BLA goal date of December. **Tone:** mgmt 0.3 · Q&A pressure 0.6 · divergence 0.3 Prepared remarks emphasize confidence in base business double-digit growth, maintained 20% EBITDA margin target ex-semaglutide, and strong H2 outlook with semaglutide resumption, while acknowledging near-term headwinds from semaglutide provision and Middle East conflict. ### Demand visibility Underlying base business (ex-lenalidomide) delivering healthy double-digit growth across all key geographies including North America, driven by new launches and favorable currency. Branded markets (India, EM, NRT) 42% of revenue, stable margins. Semaglutide demand uncertain pending supply resumption. North America generics: $236M, -41% YoY due to lenalidomide decline, but base business double-digit growth with 6 launches including bosutinib (first-to-market 400mg) and nintedanib. Emerging Markets: INR 1,833 cr, +31% YoY, 43 new product launches. India: INR 1,780 cr, +17% YoY, outpacing IPM (14.6% vs 13.5% moving quarterly). Europe: EUR 131M, flat YoY, 24 generic launches. PSAI: $91M, -5% YoY on lower API volumes. NRT integration operating model change is profit neutral but affects revenue recognition. ### Margins / costs Reported EBITDA margin 12.5%; 15.4% excluding semaglutide provision; ~18% excluding semaglutide and Middle East impacts. Management targets 20% EBITDA margin ex-semaglutide by next quarter. SG&A up 12% YoY (36% of revenue) driven by forex, freight, personnel, branded investments. Productivity plan: sales growth 10-12% faster than S&M cost growth. Gross margin 46.5% (-1,039 bps YoY) hit by lenalidomide decline, semaglutide provision (INR 240 cr), higher solvent costs from Middle East conflict. Ex-provision gross margin 49.4% (Global Generics 53.8%, PSAI 12.9%). R&D 7.1% of revenue, down 8% YoY on lower biosimilar spend. SG&A increase 75-80% attributable to adverse forex and elevated freight from Middle East crisis. Management aims to grow sales double-digit while growing associated costs low single-digit, with emerging markets sales growing 15-20%+ vs low single-digit cost growth. ### Capital allocation Net cash surplus INR 3,057 cr ($323M). CapEx INR 307 cr ($32M). Operating cash flow negative INR 216 cr pre-acquisition. Active business development: partnered with Innoviva on XACDURO, GARDP on zoliflodacin, Nestlé on Celevida GLP+. No major M&A announced; evaluating opportunities to augment organic growth in peptides, biosimilars, consumer health, innovation. Cash flow hedges: $354M hedged at INR 92.34-94.63/USD maturing by Mar 2027; RUB 2.8B hedged at 1.26/RUB. Biologics (abatacept) and peptide facilities costs hitting P&L pre-revenue; expected to turn profit-positive post-approvals. Management engaged in BD but no specific targets disclosed. INR 3,000 cr cash provides flexibility for value-accretive deals. ### Milestones - **Semaglutide API supply resumption** [at_risk]: Provision INR 240 cr for rejected batches, lost production, incentives. Targeting commercial supply resumption by November 2026. - **Abatacept BLA approval** [on_track]: FDA pre-license inspection at Bachupally facility completed June 2026 with 7 observations; response submitted. Goal date December 2026 intact. Management expects approval. - **Bosutinib 400mg US launch** [delivered]: First-to-market launch with 180-day generic exclusivity. Market size ~INR 300M. - **Nintedanib US launch** [delivered]: Complex generic for lung disease launched in US during quarter. - **Semaglutide Canada approval** [delivered]: First company to secure approval for semaglutide type 2 diabetes in Canada. Launch allocation assumes 60% generic share initially. - **Oral semaglutide India launch** [delivered]: Launched in India; building metabolic franchise with Celevida GLP+ via Nestlé collaboration. - **Toripalimab (nasopharyngeal carcinoma)** [on_track]: In-licensed novel therapy entered INR 100 cr revenue club in <2 years in India. - **XACDURO partnership (hospital-acquired bacterial pneumonia)** [new]: Partnered with Innoviva Specialty Therapeutics for South/Central America, Caribbean, Russia, CIS. ### Fears / risks - **Semaglutide API quality and supply**: Batch rejections, provision for inventory/costs, uncertain volume recovery post-November resumption; patient safety paramount but commercial impact significant. - **Abatacept regulatory approval**: FDA Form 483 with 7 observations at biologics facility; though response submitted, approval not guaranteed. Goal date December 2026. - **US tariff policy on generics**: President announcement on tariffs; details lacking but could impact US generics business (27% of revenue). Management assessing. - **Middle East conflict cost inflation**: Elevated freight costs and higher solvent costs already impacting gross margin and SG&A; duration uncertain. - **Currency volatility**: Adverse forex movement increased SG&A; hedging program in place but residual exposure remains. - **Lenalidomide revenue cliff**: Significant YoY decline in lenalidomide sales driving North America generics decline; base business must offset. - **PSAI volume weakness**: API revenues down 5% YoY and 10% sequentially on lower volume uptake; 38 DMFs filed but demand soft. - **Biologics/peptide facility cost drag**: Facilities for abatacept and peptides operational but not yet generating revenue; costs hitting P&L until approvals and supply resume. ### Key quotes > “We are working towards resolving the issue and are planning to resume semaglutide commercial supplies by November. Importantly, there is no risk to any patient who has consumed the product. Patient safety and product quality remain our” > “We remain confident of a strong second half of the fiscal with the resumption of semaglutide supplies. The strength of our base business and our ongoing productivity initiatives will continue to support double-digit base business growth” > “The underlying base business, excluding lenalidomide, continued to deliver healthy double-digit growth across all key geographies, including North America, supported by new product launches and favorable currency movements.” > “We are still, I maintain, what we discussed a few weeks ago, that we are in the neighborhood of the 20% and likely to stay, and that's what we are saying we will do in the next quarter, including the next quarter, which will not be with” > “In my opinion, we should get approval.” — Erez Israeli ## Quarter one-liners - **2027 Q1:** Dr. Reddy's Q1 FY27 revenue fell 5.6% YoY to $853M; EBITDA margin 12.5% (15.4% ex-semaglutide provision). Base business grew double-digits across geographies. Semaglutide API issues led to INR 240 cr provision; supplies expected to resume November. Abatacept BLA goal date December maintained after F - **2026 Q4:** Dr. Reddy's FY26 Q4 showed revenue decline due to a large lenalidomide shelf‑stock adjustment and margin pressure, but management highlighted double‑digit base‑business growth, semaglutide approvals and a target to lift margins above 50% in FY27. - **2026 Q3:** — - **2026 Q2:** Dr. Reddy's posted 9.8% YoY revenue growth and a stable 26.7% EBITDA margin, highlighted progress on semaglutide, abatacept and consumer‑health acquisitions while noting U.S. generic price erosion and pending regulatory approvals. - **2026 Q1:** — - **2025 Q4:** Dr. Reddy's reports record FY25 revenue >$3.8B and EBITDA >$1B, driven by NRT acquisition and generic growth; biosimilar partnerships advance; dividend recommended. - **2025 Q3:** Dr. Reddy's posted 16% YoY revenue growth and double‑digit top‑line expansion in Q3 FY 25, highlighted new launches and biosimilar progress, but analysts flagged cardiac/gastro weakness, market‑share erosion and integration timing for the newly acquired NRT business. - **2025 Q2:** Dr. Reddy's Q2 FY25: 17% YoY revenue growth to INR 8,016 cr, highest-ever quarterly sales/PBT; NRT acquisition closed, Nestlé JV operational, rituximab biosimilar EU approved, GLP-1 pipeline advancing, USFDA inspections largely cleared. ## Theme arcs - **Management tone** (deteriorating): Δ mgmt=-0.40 ## Fear persistence - **regulatory approval timing** [resolved]: 2025 Q2 - **revlimid sales sustainability** [resolved]: 2025 Q2 - **glp-1 patent and launch execution** [resolved]: 2025 Q2 - **biosimilar commercialization risk** [resolved]: 2025 Q2 - **r&d spend vs filing yield** [resolved]: 2025 Q2 - **sg&a elevation persistence** [resolved]: 2025 Q2 - **currency and geopolitical (russia)** [resolved]: 2025 Q2 - **nrt integration and nestlé jv scale-up** [resolved]: 2025 Q2 - **segment weakness** [resolved]: 2025 Q3 - **market share erosion** [resolved]: 2025 Q3 ## Guidance path 2025 Q2:maintained → 2025 Q3:maintained → 2025 Q4:vague → 2026 Q1:vague → 2026 Q2:maintained → 2026 Q3:vague → 2026 Q4:maintained → 2027 Q1:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/RDY`